Please login to the form below

Not currently logged in

Ramprasad Reddy to chair Aurobindo’s US business

Will also step down from position as full-time director

P V Ramprasad Reddy, who resigned as executive chair of the board of Indian firm Aurobindo in June, 2012, has been appointed chair of its US subsidiary, Aurobindo Pharma USA.

The decision was approved by Aurobindo's board of directors in a meeting last week, although the proposal is still subject to further approval from shareholders, with an extraordinary general meeting scheduled for September 27, 2012 to confirm the appointment.

If approved, Ramprasad Reddy will assume his new position on December 1, 2012.

In addition, Aurobindo's board also approved that Ramprasad Reddy relinquish his executive responsibilities as full-time director of the company, although he will continue as non-exectuive director.

Ramprasad Reddy also has roles at several other Aurobindo subsidiaries, which include serving as director of APL Pharma Thai Limited, Aurobindo (Datong) Bio-Pharma and Aurobindo Tongling (Datong) Pharmaceutical.

In 2008, World Pharmaceutical Frontiers named Ramprasad Reddy as one of the 35 most influential people in the pharmaceutical industry.

29th August 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Ashfield Healthcare Communications

At Ashfield Healthcare Communications, part of UDG Healthcare, there is one guiding principle that connects all our healthcare communications and...

Latest intelligence

10 tips for developing insightful pre-launch positioning
By getting your positioning right, you can build the motivational, aspirational, and resonant brand story and messaging that will allow your product to become a brand. Blue Latitude Health's Head...
White paper download: Creating experiences to improve patient outcomes
Download our white paper "Creating experiences to improve patient outcomes" to learn the steps to building an effective customer experience strategy....
Organisational Memory
In a knowledge-based industry with high labour mobility, retaining that knowledge within an organisation during a drug’s lifecycle can be tricky. If we undervalue the knowledge, experience and marketing understanding...